Provista Diagnostics to Present at The 2016 BIO International Convention

New York, NY, May 24, 2016 (GLOBE NEWSWIRE) --

Provista Diagnostics, Inc., today announces that David Reese, Ph.D., President and Chief Executive Officer, will deliver a corporate overview at the 2016 BIO International Convention, taking place June 6-9, 2016 at the Moscone Center in San Francisco, California.

“We are thrilled to have been accepted to present at this key industry conference”, said Dr. Reese. “I am looking forward to updating the investment community on Provista’s corporate and clinical developments.”

Dr. Reese will be presenting on Wednesday, June 8 at 11:30 a.m. Pacific Time in Presentation Room 2.

About Provista Diagnostics, Inc.

Provista Diagnostics is a privately held molecular diagnostics company headquartered in New York focused on developing and commercializing a new generation of proprietary blood-based diagnostic, prognostic and monitoring tests designed to address the unmet needs in cancers affecting women, such as breast and gynecologic cancers. Provista Diagnostics’ state-of-the-art, high complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and certified by the Centers for Medicare and Medicaid Services (CMS) to be compliant with the Clinical Laboratory Improvement Amendments (CLIA).

Additional information about Provista Diagnostics is available at

Information about Provista Diagnostics’ clinical trials is available at

About BIO 

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

For more information about BIO go to

Susan LaMacchia Provista Diagnostics 212-202-3174

Source:Provista Diagnostics, Inc.